View all cases
UPC CFI 148/2024
May 13, 2024·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Case details
- StatusCase ClosedActionInfringementCategoryMain Infringement Action
- Parties
- Claimants
- Sanofi Mature IP
- Sanofi Winthrop Industrie
- Sanofi-Aventis France
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Reps: Frédéric Chevallier; Agathe Michel-De Cazotte - Division
- Munich LD
- Technology
- Pharmaceuticals · Small Molecule · Pharmaceutical & Medical
- Language
- English
- First decided
- Dec 12, 2025
Documents
| Document title | Date | Public |
|---|---|---|
| Note | 2026-05-19 | Not public |
| Receipt | 2026-04-22 | Not public |
| Cover sheet | 2026-04-22 | Not public |
| Application document Defendant | 2026-04-22 | Not public |
| Receipt | 2026-04-22 | Not public |
| Cover sheet | 2026-04-22 | Not public |
| Application document Defendant | 2026-04-22 | Not public |
| Note | 2026-04-15 | Not public |
| Note | 2026-03-11 | Not public |
| action.issueDecision.decision | 2026-02-13 | Not public |
| Final Order | 2026-02-13 | Public |
| Note | 2026-02-06 | Not public |
| Receipt | 2026-02-04 | Not public |
| Cover sheet | 2026-02-04 | Not public |
| Application document Claimant | 2026-02-04 | Not public |
| Receipt | 2026-01-12 | Not public |
| Cover sheet | 2026-01-12 | Not public |
| Exhibit document Respondent | 2026-01-12 | Not public |
| Exhibit document Respondent | 2026-01-12 | Not public |
| Exhibit document Respondent | 2026-01-12 | Not public |
| Exhibit document Respondent | 2026-01-12 | Not public |
| Application document Respondent | 2026-01-12 | Not public |
| action.issueOrder.order | 2026-01-09 | Not public |
| Order | 2026-01-09 | Not public |
| action.phaseChange.caseClose | 2025-12-16 | Not public |
| Decision | 2025-12-16 | Public |
| action.issueDecision.decision | 2025-12-12 | Not public |
| Decision | 2025-12-12 | Not public |
| Other Documents | 2025-11-19 | Not public |
| Cover sheet | 2025-11-03 | Not public |
| Application document Claimant | 2025-11-03 | Not public |
| Receipt | 2025-11-03 | Not public |
| Headnote-and-Keywords | 2025-09-15 | Not public |
| Interim-Procedure-Closure | 2025-09-15 | Not public |
| Summon-Oral-Hearing | 2025-09-15 | Not public |
| summons party expert witnesses | 2025-09-15 | Not public |
| R 105.5 - 2nd interim conference - 12 Sep. 2025 | 2025-09-15 | Not public |
| Hearing-Dates | 2025-09-15 | Not public |
| R 105.5 - 2nd interim conference - 12 Sep. 2025 | 2025-09-15 | Not public |
| oral hearing reference - IC | 2025-09-15 | Not public |
| oral hearing reference - IC | 2025-09-15 | Not public |
| Fix-Interim-Conference-Date | 2025-09-10 | Not public |
| Interim-Conference-Decision | 2025-09-10 | Not public |
| Written-Procedure-Closure | 2025-09-10 | Not public |
| Receipt | 2025-09-02 | Not public |
| Receipt | 2025-09-02 | Not public |
| Application | 2025-09-01 | Not public |
| 2025 09 01 Sanofi vs. Zentiva_ZENTIVA_Application R. 176 RoP_R. 9 RoP_PDFA | 2025-09-01 | Not public |
| DFMP_119_Copy_of_the EPO_TBA_communication_on_issuance_of_written_decision_of_18_August_2025 | 2025-09-01 | Not public |
| DFMP_118_Overview_Document_evidencing_the_relevant_facts_as_well_as_reference_to_the_most_important_citation_therein | 2025-09-01 | Not public |
| Receipt | 2025-08-11 | Not public |
| Exhibit_DFMP_D117_Expert_Opinion_of_Prof_Mueller | 2025-08-08 | Not public |
| 2025_08_08_Sanovi_vs._Zentiva_ZENTIVA_Counterclaim_for_revocation_Rule_9_brief_experts | 2025-08-08 | Not public |
| Exhibit_DFMP_D116_PM_5.1_Declaration_by_Dr._Samuel_Denmeade | 2025-08-08 | Not public |
| Anonymized decision bis - 22248-2025 - 17.07.2025 | 2025-08-07 | Not public |
| Anonymizd decision 22248-2025 - 17.07.2025 | 2025-08-07 | Not public |
| Headnote-and-Keywords | 2025-07-17 | Not public |
| Headnote-and-Keywords | 2025-07-17 | Not public |
| R 105.5 RoP | 2025-07-17 | Public |
| R 105.5 RoP | 2025-07-17 | Not public |
| R 105.5 RoP | 2025-07-17 | Public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-change-of-a-representative | 2025-07-10 | Not public |
| Acknowledgement-of-lodging | 2025-07-08 | Not public |
| 2025 07 08 Sanovi vs. Zentiva_ZENTIVA_Rejoinder Infringement_Reply Counterclaim_signed | 2025-07-08 | Not public |
| Exhibit_DFMP_D115_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_15_signed | 2025-07-08 | Not public |
| Exhibit_DFMP_D114_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_17_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_14_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_16_signed | 2025-07-08 | Not public |
| Acknowledgement-of-lodging | 2025-07-08 | Not public |
| Exhibit_DFMP_D114_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_14_signed | 2025-07-08 | Not public |
| 2025 07 08 Sanovi vs. Zentiva_ZENTIVA_Rejoinder Infringement_Reply Counterclaim_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_16_signed | 2025-07-08 | Not public |
| Exhibit_DFMP_D115_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_17_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_15_signed | 2025-07-08 | Not public |
| Acknowledgement-of-lodging | 2025-07-08 | Not public |
| Exhibit_TW_D_15_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_16_signed | 2025-07-08 | Not public |
| Exhibit_DFMP_D114_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_17_signed | 2025-07-08 | Not public |
| 2025 07 08 Sanovi vs. Zentiva_ZENTIVA_Rejoinder Infringement_Reply Counterclaim_signed | 2025-07-08 | Not public |
| Exhibit_TW_D_14_signed | 2025-07-08 | Not public |
| Exhibit_DFMP_D115_signed | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Application-RoP293-Receipt | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-07-08 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application-RoP293 | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Application | 2025-06-27 | Not public |
| Headnote-and-Keywords | 2025-06-27 | Not public |
| Outcome of the Order | 2025-06-27 | Not public |
| R 333 final signed | 2025-06-27 | Public |
| Comments | 2025-06-09 | Not public |
| R.333.2.2 - oberservations | 2025-06-04 | Not public |
| Acknowledgement-of-lodging | 2025-06-03 | Not public |
| Exhibit TW D13_signed | 2025-05-22 | Not public |
| Sanofi_v_Zentiva_ZENTIVA_Request for panel review | 2025-05-22 | Not public |
| Comments | 2025-05-15 | Not public |
| Preliminary_Objection_DecisionOutcome | 2025-05-14 | Not public |
| R 20.2 | 2025-05-14 | Not public |
| R 20.2 | 2025-05-14 | Public |
| hearing reference | 2025-05-14 | Not public |
| hearing reference | 2025-05-14 | Not public |
| confidentialty - oberservations | 2025-05-11 | Not public |
| order 8 May 2025 tailored | 2025-05-11 | Not public |
| order 8 May 2025 tailored | 2025-05-11 | Not public |
| Headnote-and-Keywords | 2025-05-09 | Not public |
| Outcome of the Order | 2025-05-08 | Not public |
| final order | 2025-05-08 | Not public |
| final order | 2025-05-08 | Public |
| Outcome of the Order | 2025-05-08 | Not public |
| final order | 2025-05-08 | Public |
| final order | 2025-05-08 | Not public |
| final order | 2025-05-08 | Public |
| final order | 2025-05-08 | Not public |
| Exhibit TW D 11_signed | 2025-04-09 | Not public |
| Exhibit TW D 12B_373-740_signed | 2025-04-09 | Not public |
| Exhibit TW D 10_signed | 2025-04-09 | Not public |
| 2025 04 09 Sanofi_v_Zentiva_ZENTIVA_Reply to Sanofi Comments No 2 R. 105_signed | 2025-04-09 | Not public |
| Exhibit TW D 9_signed | 2025-04-09 | Not public |
| Exhibit TW D 12A_1-372_signed | 2025-04-09 | Not public |
| Outcome of the Order | 2025-03-21 | Not public |
| 262 A - final | 2025-03-21 | Public |
| 262 A - final | 2025-03-21 | Public |
| Comments No. 2 Rule 105(5) RoP (Zentiva - redacted) | 2025-03-20 | Not public |
| Exhibit No. F.05 | 2025-03-20 | Not public |
| Exhibit No. B.01.1.c | 2025-03-20 | Not public |
| Exhibit No. F.03 | 2025-03-20 | Not public |
| Exhibit No. F.04 | 2025-03-20 | Not public |
| Comments No. 2 Rule 105(5) RoP (Zentiva - unredacted) | 2025-03-20 | Not public |
| Exhibit No. F.06 | 2025-03-20 | Not public |
| Exhibit No. B.01.1.2.b | 2025-03-20 | Not public |
| Comments No. 2 Rule 105(5) RoP (Zentiva - unredacted) | 2025-03-20 | Not public |
| comments | 2025-02-27 | Not public |
| Receipt | 2025-02-13 | Not public |
| 2025 02 12 Sanofi vs. Zentiva_ZENTIVA_Comment on Order ORD_3586-2025_Application under R. 263 RoP(40963292.1)_sig | 2025-02-12 | Not public |
| 2025 02 12 Sanofi vs. Zentiva_ZENTIVA_Comment on Order ORD_3586-2025_Application under R. 263 RoP(40963292.1)_sig | 2025-02-12 | Not public |
| Comments 263 RoP | 2025-01-29 | Not public |
| Final Order R 105.5 anonymized | 2025-01-27 | Not public |
| R 105.5 - 15 Jan. 2025 | 2025-01-22 | Public |
| R 105.5 - 15 Jan. 2025 | 2025-01-22 | Not public |
| Template-Order | 2025-01-22 | Not public |
| Exhibit No. D.04 - New redacted version | 2025-01-17 | Not public |
| Outcome of the Order | 2025-01-17 | Not public |
| R 305 second - final | 2025-01-17 | Public |
| Hearing Reference | 2025-01-16 | Not public |
| Hearing Reference | 2025-01-16 | Not public |
| App_57840/2024 UPC_CFI_148/2024 - 262A - anonymized | 2025-01-15 | Not public |
| R 262 A - final | 2025-01-14 | Public |
| R 262 A - final | 2025-01-14 | Not public |
| Hearing-Dates | 2025-01-13 | Not public |
| R 305 second- oral comments | 2025-01-13 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Written Comments | 2025-01-10 | Not public |
| Receipt | 2025-01-09 | Not public |
| Application | 2025-01-09 | Not public |
| Exhibit No. A.02.2 | 2025-01-09 | Not public |
| Hearing-Dates | 2025-01-09 | Not public |
| R 19 - oral argument hearing | 2025-01-09 | Not public |
| R 305-310 final | 2025-01-07 | Public |
| R 262 A - comments | 2025-01-03 | Not public |
| Outcome of the Order | 2024-12-19 | Not public |
| extension request | 2024-12-19 | Public |
| Receipt | 2024-12-13 | Not public |
| Receipt | 2024-12-13 | Not public |
| Reply and Defence | 2024-12-13 | Not public |
| 2024_12_10_Sanofi_vs._Zentiva_ZENTIVA_Application_extension_of_deadline_RoP_9_334_336 | 2024-12-10 | Not public |
| R 37.2 final signed | 2024-11-12 | Public |
| 2024 11 12 Sanofi vs. Zentiva_ZENTIVA_Comment on R.262A RoP_sig | 2024-11-12 | Not public |
| 2024 11 12 Sanofi vs. Zentiva_ZENTIVA_Comment on R.262A RoP_sig | 2024-11-12 | Not public |
| 2024 11 12 Sanofi vs. Zentiva_ZENTIVA_Comment on R.262A RoP_sig | 2024-11-12 | Not public |
| 2024 11 12 Sanofi vs. Zentiva_ZENTIVA_Comment on R.305 RoP_sig | 2024-11-12 | Not public |
| 2024 11 12 Sanofi vs. Zentiva_ZENTIVA_Comment on R.305 RoP_sig | 2024-11-12 | Not public |
| 2024 11 12 Sanofi vs. Zentiva_ZENTIVA_Comment on R.305 RoP_sig | 2024-11-12 | Not public |
| Comment on application RoP 262A | 2024-11-05 | Not public |
| Outcome of the Order | 2024-11-05 | Not public |
| Comment Application RoP 305 | 2024-11-05 | Public |
| Receipt | 2024-11-04 | Not public |
| Application | 2024-11-01 | Not public |
| Exhibit No. D.04 (REDACTED) | 2024-11-01 | Not public |
| Exhibit No. D.04 (UNREDACTED) | 2024-11-01 | Not public |
| Acknowledgement-of-lodging | 2024-11-01 | Not public |
| Reply and Defence | 2024-11-01 | Not public |
| Acknowledgement-of-lodging | 2024-11-01 | Not public |
| Reply and Defence | 2024-11-01 | Not public |
| Acknowledgement-of-lodging | 2024-11-01 | Not public |
| Exhibit No. B.04.4 | 2024-11-01 | Not public |
| Exhibit No. B.22 | 2024-11-01 | Not public |
| Exhibit No. B.06 | 2024-11-01 | Not public |
| Exhibit No. B.04.7 | 2024-11-01 | Not public |
| Exhibit No. B.04.8 | 2024-11-01 | Not public |
| Exhibit No. B.12 | 2024-11-01 | Not public |
| Exhibit No. B.22.1 | 2024-11-01 | Not public |
| Exhibit No. D.01.4 (2) | 2024-11-01 | Not public |
| Exhibit No. B.18 | 2024-11-01 | Not public |
| Exhibit No. B.17.1 | 2024-11-01 | Not public |
| Exhibit No. B.25 (6) | 2024-11-01 | Not public |
| Exhibit No. D.01.4 (1) | 2024-11-01 | Not public |
| Exhibit No. B.20 | 2024-11-01 | Not public |
| Exhibit No. G.04 | 2024-11-01 | Not public |
| Exhibit No. B.07.6 | 2024-11-01 | Not public |
| Exhibit No. G.07 | 2024-11-01 | Not public |
| Exhibit No. B.07.4 | 2024-11-01 | Not public |
| Exhibit No. B.04.5 | 2024-11-01 | Not public |
| Exhibit No. B.13 | 2024-11-01 | Not public |
| Exhibit No. B.09.1 | 2024-11-01 | Not public |
| Exhibit No. B.03 | 2024-11-01 | Not public |
| Exhibit No. B.16.1 | 2024-11-01 | Not public |
| Exhibit No. D.01.4 (3) | 2024-11-01 | Not public |
| Exhibit No. B.29 (1) | 2024-11-01 | Not public |
| Exhibit No. B.04.1 | 2024-11-01 | Not public |
| Exhibit No. B.04.2 | 2024-11-01 | Not public |
| Exhibit No. D.04 (UNREDACTED) | 2024-11-01 | Not public |
| Exhibit No. B.11 | 2024-11-01 | Not public |
| Exhibit No. F.01.1 (1) | 2024-11-01 | Not public |
| Reply and Defence | 2024-11-01 | Not public |
| Exhibit No. 0.4 | 2024-11-01 | Not public |
| Exhibit No. B.19 | 2024-11-01 | Not public |
| Exhibit No. B.07.5 | 2024-11-01 | Not public |
| Exhibit No. D.03.3 | 2024-11-01 | Not public |
| Exhibit No. B.21 | 2024-11-01 | Not public |
| Exhibit No. B.27 | 2024-11-01 | Not public |
| Exhibit No. B.25 (3) | 2024-11-01 | Not public |
| Exhibit No. B.25 (2) | 2024-11-01 | Not public |
| Exhibit No. B.25 (5) | 2024-11-01 | Not public |
| Exhibit No. B.16 | 2024-11-01 | Not public |
| Exhibit No. G.01 | 2024-11-01 | Not public |
| Exhibit No. B.10 | 2024-11-01 | Not public |
| Exhibit No. B.17.2 | 2024-11-01 | Not public |
| Exhibit No. B.26 | 2024-11-01 | Not public |
| Exhibit No. B.05.1 | 2024-11-01 | Not public |
| Exhibit No. B.04.9 | 2024-11-01 | Not public |
| Exhibit No. B.22.2 | 2024-11-01 | Not public |
| Exhibit No. B.28 | 2024-11-01 | Not public |
| Exhibit No. B.07.2 | 2024-11-01 | Not public |
| Exhibit No. F.01.1 (2) | 2024-11-01 | Not public |
| Exhibit No. B.25 (4) | 2024-11-01 | Not public |
| Exhibit No. G.06 | 2024-11-01 | Not public |
| Exhibit No. B.04.3 | 2024-11-01 | Not public |
| Exhibit No. B.15 | 2024-11-01 | Not public |
| Exhibit No. B.25 (1) | 2024-11-01 | Not public |
| Exhibit No. B.08 | 2024-11-01 | Not public |
| Exhibit No. D.04 (UNREDACTED) | 2024-11-01 | Not public |
| Exhibit No. D.03.2 | 2024-11-01 | Not public |
| Exhibit No. B.17 | 2024-11-01 | Not public |
| Exhibit No. G.02 | 2024-11-01 | Not public |
| Exhibit No. B.24 | 2024-11-01 | Not public |
| Exhibit No. B.14 | 2024-11-01 | Not public |
| Exhibit No. B.01.1b | 2024-11-01 | Not public |
| Exhibit No. G.05 | 2024-11-01 | Not public |
| Exhibit No. F.01.1 (3) | 2024-11-01 | Not public |
| Exhibit No. B.07.1 | 2024-11-01 | Not public |
| Exhibit No. B.29 (2) | 2024-11-01 | Not public |
| Exhibit No. F.01 | 2024-11-01 | Not public |
| Exhibit No. B.09 | 2024-11-01 | Not public |
| Exhibit No. B.22.3 | 2024-11-01 | Not public |
| Exhibit No. B.07.3 | 2024-11-01 | Not public |
| Exhibit No. A.02 | 2024-11-01 | Not public |
| Exhibit No. D.01.3 | 2024-11-01 | Not public |
| Exhibit No. G.03 | 2024-11-01 | Not public |
| Exhibit No. B.05 | 2024-11-01 | Not public |
| Exhibit No. B.04.6 | 2024-11-01 | Not public |
| Exhibit No. F.02 | 2024-11-01 | Not public |
| Exhibit No. A.02.1 | 2024-10-23 | Not public |
| Exhibit No. A.02.1 | 2024-10-23 | Not public |
| Application | 2024-10-23 | Not public |
| 2024 10 11 Sanofi vs. Zentiva Comment on Procedural Order of 1 October 2024 on bifurcation(40172664.1) | 2024-10-11 | Not public |
| 2024 10 11 Sanofi vs. Zentiva Comment on Procedural Order of 1 October 2024 on bifurcation(40172664.1) | 2024-10-11 | Not public |
| 2024 10 11 Sanofi vs. Zentiva Comment on Procedural Order of 1 October 2024 on bifurcation(40172664.1) | 2024-10-11 | Not public |
| 2024 10 11 Sanofi vs. Zentiva Comment on Response to Preliminary Objection of 14. July 2024(40168894.1) | 2024-10-11 | Not public |
| 2024 10 11 Sanofi vs. Zentiva Comment on Response to Preliminary Objection of 14. July 2024(40168894.1) | 2024-10-11 | Not public |
| 2024 10 11 Sanofi vs. Zentiva Comment on Response to Preliminary Objection of 14. July 2024(40168894.1) | 2024-10-11 | Not public |
| Comments on bifurcation | 2024-10-10 | Not public |
| Comments on bifurcation | 2024-10-07 | Not public |
| Comments on bifurcation | 2024-10-07 | Not public |
| Comments on bifurcation | 2024-10-07 | Not public |
| Comments on bifurcation | 2024-10-07 | Not public |
| Comments on bifurcation | 2024-10-07 | Not public |
| Comments on bifurcation | 2024-10-07 | Not public |
| Comments on bifurcation | 2024-10-07 | Not public |
| Comments on bifurcation | 2024-10-07 | Not public |
| Comments on bifurcation | 2024-10-07 | Not public |
| Comments on bifurcation | 2024-10-07 | Not public |
| R 37.2 - comments | 2024-10-01 | Not public |
| R 19 - comments | 2024-10-01 | Not public |
| Hearing-Dates | 2024-09-16 | Not public |
| scheduling - final | 2024-09-16 | Public |
| Panel-Appointment | 2024-09-16 | Not public |
| Comments | 2024-09-13 | Not public |
| Comments | 2024-09-13 | Not public |
| Comments | 2024-09-13 | Not public |
| Comments | 2024-09-13 | Not public |
| Comments | 2024-09-13 | Not public |
| Comments | 2024-09-13 | Not public |
| Comments | 2024-09-13 | Not public |
| Comments | 2024-09-13 | Not public |
| Comments | 2024-09-13 | Not public |
| Comments | 2024-09-13 | Not public |
| 2024 09 13 Sanofi vs. Zentiva Comment on Preliminary Order of 10_09_2024 | 2024-09-13 | Not public |
| 2024 09 13 Sanofi vs. Zentiva Comment on Preliminary Order of 10_09_2024 | 2024-09-13 | Not public |
| 2024 09 13 Sanofi vs. Zentiva Comment on Preliminary Order of 10_09_2024 | 2024-09-13 | Not public |
| Comments | 2024-09-13 | Not public |
| scheduling - comments | 2024-09-10 | Not public |
| Hearing-Dates | 2024-09-10 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-09-03 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-09-03 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-09-03 | Not public |
| Acknowledgement-of-lodging | 2024-09-02 | Not public |
| DFMP D26 - Attard et al. | 2024-09-02 | Not public |
| DFMP D35 - Leaflet Aventis Oncology 2003 | 2024-09-02 | Not public |
| DFMP D1 - Sanofi-Aventis - XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone | 2024-09-02 | Not public |
| TW D 5 - FR SMPC Cabazitaxel | 2024-09-02 | Not public |
| TW D 3 - Report EU Commission | 2024-09-02 | Not public |
| DFMP D72 - Scher et al. | 2024-09-02 | Not public |
| DFMP D102 - Tannock_Clin. Oncol. 1989 | 2024-09-02 | Not public |
| DFMP D9 - Galletti et al. | 2024-09-02 | Not public |
| DFMP D110 - Consolidated List of documents EPO | 2024-09-02 | Not public |
| TW D 6 - FR Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP D37 - Winquist et al. | 2024-09-02 | Not public |
| DFMP 1 - Confirmation of payment of court fees | 2024-09-02 | Not public |
| TW D 7 - DE SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP D104 - Tannock_Clin. Oncol. 1996 | 2024-09-02 | Not public |
| DFMP P7 - Priority document US 61_389969 | 2024-09-02 | Not public |
| DFMP D2 - National Horizon Scanning Centre | 2024-09-02 | Not public |
| DFMP D3b - Further blog post by Dr. Mirtsching July 6 2007 | 2024-09-02 | Not public |
| DFMP D90 - Goetz et al. | 2024-09-02 | Not public |
| DFMP D103 - Fossa. et al. | 2024-09-02 | Not public |
| DFMP P5 - Priority document US 61_369929 | 2024-09-02 | Not public |
| TW D 6 - FR Leaflet Cabazitaxel | 2024-09-02 | Not public |
| TW D 5 - FR SMPC Cabazitaxel | 2024-09-02 | Not public |
| TW D 4 - ANSM Cabazitaxel | 2024-09-02 | Not public |
| DFMP D111 - INN Publication 2008 | 2024-09-02 | Not public |
| DFMP P1 - Priority document US 61_256160 | 2024-09-02 | Not public |
| 2024 09 02 Sanofi vs. Zentiva Statement of Defence and Counterclaim for Revoc | 2024-09-02 | Not public |
| TW D 8 - DE Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP D112 - Excerpt from the online National Cancer Institute_s Drug Dictionary re. cabazitaxel | 2024-09-02 | Not public |
| DFMP D14 - FDA label for docetaxel (Taxotere) 2007 | 2024-09-02 | Not public |
| DFMP D18 - EMA Guideline on the Evaluation of Anticancer Medicinal Products in Man 2006 | 2024-09-02 | Not public |
| DFMP D11 - Les Echos_ 22 Dec 2009 | 2024-09-02 | Not public |
| DFMP D29 - Tannock et al. | 2024-09-02 | Not public |
| DFMP P2 - Priority document US 61_293903 | 2024-09-02 | Not public |
| DFMP D7 - Beardsley et al. | 2024-09-02 | Not public |
| DFMP D109 - Albarqouni | 2024-09-02 | Not public |
| TW D 4 - ANSM Cabazitaxel | 2024-09-02 | Not public |
| DFMP D108 - Barraclough and Davis | 2024-09-02 | Not public |
| DFMP D3a - Blog post by Dr. Barry Mirtsching 12 October 2007 | 2024-09-02 | Not public |
| DFMP D15 - de Bono et al. | 2024-09-02 | Not public |
| DFMP D10 - Sanofi-Aventis Press Release_ 21 December 2009 | 2024-09-02 | Not public |
| DFMP D4 - Mita et al. | 2024-09-02 | Not public |
| DFMP P3 - Priority document US 61_355834 | 2024-09-02 | Not public |
| DFMP D11 - Les Echos_ 22 Dec 2009 | 2024-09-02 | Not public |
| DFMP D105 - Sava et al. | 2024-09-02 | Not public |
| DFMP D25 - Correspondence_Lancet_2011_377_121-122 | 2024-09-02 | Not public |
| TW D 7 - DE SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP D21 - EMA Assessment Report for Jevtana (cabazitaxel) January 20 2011 | 2024-09-02 | Not public |
| DFMP D113 - US Code of Federal Regulations Title 21_Chapter I_Part 314 | 2024-09-02 | Not public |
| TW D 8 - DE Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP D91 - Bissery et al. | 2024-09-02 | Not public |
| DFMP P6 - Priority document US 61_383933 | 2024-09-02 | Not public |
| TW D 2 - Medicines for Europe | 2024-09-02 | Not public |
| DFMP D38 - Sanofi Press Release_September 17 2007 | 2024-09-02 | Not public |
| DFMP P4 - Priority document US 61_355888 | 2024-09-02 | Not public |
| DFMP D13 - Pivot et al. | 2024-09-02 | Not public |
| Acknowledgement-of-lodging | 2024-09-02 | Not public |
| DFMP D1 - Sanofi-Aventis - XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone | 2024-09-02 | Not public |
| DFMP D14 - FDA label for docetaxel (Taxotere) 2007 | 2024-09-02 | Not public |
| TW D 5 - FR SMPC Cabazitaxel | 2024-09-02 | Not public |
| TW D 7 - DE SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP D105 - Sava et al. | 2024-09-02 | Not public |
| DFMP P2 - Priority document US 61_293903 | 2024-09-02 | Not public |
| DFMP D7 - Beardsley et al. | 2024-09-02 | Not public |
| DFMP D3a - Blog post by Dr. Barry Mirtsching 12 October 2007 | 2024-09-02 | Not public |
| DFMP P3 - Priority document US 61_355834 | 2024-09-02 | Not public |
| DFMP D37 - Winquist et al. | 2024-09-02 | Not public |
| DFMP D110 - Consolidated List of documents EPO | 2024-09-02 | Not public |
| DFMP D13 - Pivot et al. | 2024-09-02 | Not public |
| TW D 7 - DE SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP D38 - Sanofi Press Release_September 17 2007 | 2024-09-02 | Not public |
| TW D 2 - Medicines for Europe | 2024-09-02 | Not public |
| DFMP D9 - Galletti et al. | 2024-09-02 | Not public |
| DFMP D18 - EMA Guideline on the Evaluation of Anticancer Medicinal Products in Man 2006 | 2024-09-02 | Not public |
| TW D 4 - ANSM Cabazitaxel | 2024-09-02 | Not public |
| DFMP D3b - Further blog post by Dr. Mirtsching July 6 2007 | 2024-09-02 | Not public |
| DFMP P5 - Priority document US 61_369929 | 2024-09-02 | Not public |
| DFMP D108 - Barraclough and Davis | 2024-09-02 | Not public |
| TW D 4 - ANSM Cabazitaxel | 2024-09-02 | Not public |
| 2024 09 02 Sanofi vs. Zentiva Statement of Defence and Counterclaim for Revoc | 2024-09-02 | Not public |
| DFMP D113 - US Code of Federal Regulations Title 21_Chapter I_Part 314 | 2024-09-02 | Not public |
| DFMP D102 - Tannock_Clin. Oncol. 1989 | 2024-09-02 | Not public |
| TW D 8 - DE Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP 1 - Confirmation of payment of court fees | 2024-09-02 | Not public |
| DFMP D111 - INN Publication 2008 | 2024-09-02 | Not public |
| DFMP D4 - Mita et al. | 2024-09-02 | Not public |
| DFMP P1 - Priority document US 61_256160 | 2024-09-02 | Not public |
| DFMP D21 - EMA Assessment Report for Jevtana (cabazitaxel) January 20 2011 | 2024-09-02 | Not public |
| DFMP D29 - Tannock et al. | 2024-09-02 | Not public |
| DFMP D90 - Goetz et al. | 2024-09-02 | Not public |
| DFMP D11 - Les Echos_ 22 Dec 2009 | 2024-09-02 | Not public |
| DFMP D109 - Albarqouni | 2024-09-02 | Not public |
| DFMP D10 - Sanofi-Aventis Press Release_ 21 December 2009 | 2024-09-02 | Not public |
| DFMP D104 - Tannock_Clin. Oncol. 1996 | 2024-09-02 | Not public |
| DFMP D91 - Bissery et al. | 2024-09-02 | Not public |
| DFMP D2 - National Horizon Scanning Centre | 2024-09-02 | Not public |
| DFMP D26 - Attard et al. | 2024-09-02 | Not public |
| DFMP P6 - Priority document US 61_383933 | 2024-09-02 | Not public |
| DFMP D35 - Leaflet Aventis Oncology 2003 | 2024-09-02 | Not public |
| TW D 6 - FR Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP D11 - Les Echos_ 22 Dec 2009 | 2024-09-02 | Not public |
| TW D 3 - Report EU Commission | 2024-09-02 | Not public |
| DFMP D72 - Scher et al. | 2024-09-02 | Not public |
| TW D 6 - FR Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP D103 - Fossa. et al. | 2024-09-02 | Not public |
| DFMP P4 - Priority document US 61_355888 | 2024-09-02 | Not public |
| DFMP D25 - Correspondence_Lancet_2011_377_121-122 | 2024-09-02 | Not public |
| DFMP D112 - Excerpt from the online National Cancer Institute_s Drug Dictionary re. cabazitaxel | 2024-09-02 | Not public |
| TW D 5 - FR SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP D15 - de Bono et al. | 2024-09-02 | Not public |
| DFMP P7 - Priority document US 61_389969 | 2024-09-02 | Not public |
| TW D 8 - DE Leaflet Cabazitaxel | 2024-09-02 | Not public |
| TW D 2 - Medicines for Europe | 2024-09-02 | Not public |
| DFMP D112 - Excerpt from the online National Cancer Institute_s Drug Dictionary re. cabazitaxel | 2024-09-02 | Not public |
| TW D 8 - DE Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP D11 - Les Echos_ 22 Dec 2009 | 2024-09-02 | Not public |
| DFMP D2 - National Horizon Scanning Centre | 2024-09-02 | Not public |
| DFMP D108 - Barraclough and Davis | 2024-09-02 | Not public |
| TW D 7 - DE SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP D110 - Consolidated List of documents EPO | 2024-09-02 | Not public |
| DFMP D91 - Bissery et al. | 2024-09-02 | Not public |
| DFMP P1 - Priority document US 61_256160 | 2024-09-02 | Not public |
| DFMP P2 - Priority document US 61_293903 | 2024-09-02 | Not public |
| TW D 5 - FR SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP D3a - Blog post by Dr. Barry Mirtsching 12 October 2007 | 2024-09-02 | Not public |
| DFMP D111 - INN Publication 2008 | 2024-09-02 | Not public |
| DFMP D37 - Winquist et al. | 2024-09-02 | Not public |
| DFMP 1 - Confirmation of payment of court fees | 2024-09-02 | Not public |
| DFMP D13 - Pivot et al. | 2024-09-02 | Not public |
| TW D 4 - ANSM Cabazitaxel | 2024-09-02 | Not public |
| DFMP D14 - FDA label for docetaxel (Taxotere) 2007 | 2024-09-02 | Not public |
| DFMP D102 - Tannock_Clin. Oncol. 1989 | 2024-09-02 | Not public |
| DFMP D72 - Scher et al. | 2024-09-02 | Not public |
| DFMP P5 - Priority document US 61_369929 | 2024-09-02 | Not public |
| DFMP D103 - Fossa. et al. | 2024-09-02 | Not public |
| TW D 8 - DE Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP D38 - Sanofi Press Release_September 17 2007 | 2024-09-02 | Not public |
| TW D 5 - FR SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP D109 - Albarqouni | 2024-09-02 | Not public |
| TW D 7 - DE SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP P3 - Priority document US 61_355834 | 2024-09-02 | Not public |
| DFMP D1 - Sanofi-Aventis - XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone | 2024-09-02 | Not public |
| DFMP D104 - Tannock_Clin. Oncol. 1996 | 2024-09-02 | Not public |
| DFMP D18 - EMA Guideline on the Evaluation of Anticancer Medicinal Products in Man 2006 | 2024-09-02 | Not public |
| DFMP D113 - US Code of Federal Regulations Title 21_Chapter I_Part 314 | 2024-09-02 | Not public |
| DFMP D11 - Les Echos_ 22 Dec 2009 | 2024-09-02 | Not public |
| DFMP P7 - Priority document US 61_389969 | 2024-09-02 | Not public |
| DFMP D15 - de Bono et al. | 2024-09-02 | Not public |
| DFMP D29 - Tannock et al. | 2024-09-02 | Not public |
| DFMP D10 - Sanofi-Aventis Press Release_ 21 December 2009 | 2024-09-02 | Not public |
| DFMP P4 - Priority document US 61_355888 | 2024-09-02 | Not public |
| DFMP D25 - Correspondence_Lancet_2011_377_121-122 | 2024-09-02 | Not public |
| DFMP P6 - Priority document US 61_383933 | 2024-09-02 | Not public |
| TW D 6 - FR Leaflet Cabazitaxel | 2024-09-02 | Not public |
| TW D 4 - ANSM Cabazitaxel | 2024-09-02 | Not public |
| DFMP D9 - Galletti et al. | 2024-09-02 | Not public |
| TW D 3 - Report EU Commission | 2024-09-02 | Not public |
| DFMP D35 - Leaflet Aventis Oncology 2003 | 2024-09-02 | Not public |
| DFMP D26 - Attard et al. | 2024-09-02 | Not public |
| DFMP D3b - Further blog post by Dr. Mirtsching July 6 2007 | 2024-09-02 | Not public |
| DFMP D105 - Sava et al. | 2024-09-02 | Not public |
| DFMP D4 - Mita et al. | 2024-09-02 | Not public |
| DFMP D21 - EMA Assessment Report for Jevtana (cabazitaxel) January 20 2011 | 2024-09-02 | Not public |
| DFMP D90 - Goetz et al. | 2024-09-02 | Not public |
| TW D 6 - FR Leaflet Cabazitaxel | 2024-09-02 | Not public |
| 2024 09 02 Sanofi vs. Zentiva Statement of Defence and Counterclaim for Revoc | 2024-09-02 | Not public |
| DFMP D7 - Beardsley et al. | 2024-09-02 | Not public |
| Acknowledgement-of-lodging | 2024-09-02 | Not public |
| DFMP D110 - Consolidated List of documents EPO | 2024-09-02 | Not public |
| DFMP P4 - Priority document US 61_355888 | 2024-09-02 | Not public |
| Exhibit TW D 8 - DE Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP 1 - Confirmation of payment of court fees | 2024-09-02 | Not public |
| DFMP D2 - National Horizon Scanning Centre | 2024-09-02 | Not public |
| DFMP D10 - Sanofi-Aventis Press Release_ 21 December 2009 | 2024-09-02 | Not public |
| Exhibit TW D 6 - FR Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP D11 - Les Echos_ 22 Dec 2009 | 2024-09-02 | Not public |
| DFMP D7 - Beardsley et al. | 2024-09-02 | Not public |
| DFMP D21 - EMA Assessment Report for Jevtana (cabazitaxel) January 20 2011 | 2024-09-02 | Not public |
| DFMP D3b - Further blog post by Dr. Mirtsching July 6 2007 | 2024-09-02 | Not public |
| DFMP D72 - Scher et al. | 2024-09-02 | Not public |
| DFMP D29 - Tannock et al. | 2024-09-02 | Not public |
| DFMP D3a - Blog post by Dr. Barry Mirtsching 12 October 2007 | 2024-09-02 | Not public |
| DFMP D9 - Galletti et al. | 2024-09-02 | Not public |
| DFMP D1 - Sanofi-Aventis - XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone | 2024-09-02 | Not public |
| DFMP D105 - Sava et al. | 2024-09-02 | Not public |
| TW D 5 - FR SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP D35 - Leaflet Aventis Oncology 2003 | 2024-09-02 | Not public |
| Exhibit TW D 7 - DE SMPC Cabazitaxel | 2024-09-02 | Not public |
| TW D 5 - FR SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP P7 - Priority document US 61_389969 | 2024-09-02 | Not public |
| Exhibit TW D 2 - Medicines for Europe | 2024-09-02 | Not public |
| DFMP D109 - Albarqouni | 2024-09-02 | Not public |
| DFMP D104 - Tannock_Clin. Oncol. 1996 | 2024-09-02 | Not public |
| DFMP P2 - Priority document US 61_293903 | 2024-09-02 | Not public |
| DFMP D13 - Pivot et al. | 2024-09-02 | Not public |
| DFMP D113 - US Code of Federal Regulations Title 21_Chapter I_Part 314 | 2024-09-02 | Not public |
| TW D 3 - Report EU Commission | 2024-09-02 | Not public |
| DFMP D112 - Excerpt from the online National Cancer Institute_s Drug Dictionary re. cabazitaxel | 2024-09-02 | Not public |
| DFMP D18 - EMA Guideline on the Evaluation of Anticancer Medicinal Products in Man 2006 | 2024-09-02 | Not public |
| DFMP D25 - Correspondence_Lancet_2011_377_121-122 | 2024-09-02 | Not public |
| DFMP D11 - Les Echos_ 22 Dec 2009 | 2024-09-02 | Not public |
| DFMP D90 - Goetz et al. | 2024-09-02 | Not public |
| DFMP D91 - Bissery et al. | 2024-09-02 | Not public |
| DFMP P5 - Priority document US 61_369929 | 2024-09-02 | Not public |
| 2024 09 02 Sanofi vs. Zentiva Statement of Defence and Counterclaim for Revoc | 2024-09-02 | Not public |
| DFMP D102 - Tannock_Clin. Oncol. 1989 | 2024-09-02 | Not public |
| Exhibit TW D 8 - DE Leaflet Cabazitaxel | 2024-09-02 | Not public |
| DFMP D37 - Winquist et al. | 2024-09-02 | Not public |
| DFMP D15 - de Bono et al. | 2024-09-02 | Not public |
| DFMP D38 - Sanofi Press Release_September 17 2007 | 2024-09-02 | Not public |
| Exhibit TW D 7 - DE SMPC Cabazitaxel | 2024-09-02 | Not public |
| DFMP D111 - INN Publication 2008 | 2024-09-02 | Not public |
| Exhibit TW D 4 - ANSM Cabazitaxel | 2024-09-02 | Not public |
| DFMP P1 - Priority document US 61_256160 | 2024-09-02 | Not public |
| DFMP P3 - Priority document US 61_355834 | 2024-09-02 | Not public |
| DFMP P6 - Priority document US 61_383933 | 2024-09-02 | Not public |
| DFMP D108 - Barraclough and Davis | 2024-09-02 | Not public |
| DFMP D4 - Mita et al. | 2024-09-02 | Not public |
| DFMP D26 - Attard et al. | 2024-09-02 | Not public |
| DFMP D14 - FDA label for docetaxel (Taxotere) 2007 | 2024-09-02 | Not public |
| Exhibit TW D 4 - ANSM Cabazitaxel | 2024-09-02 | Not public |
| DFMP D103 - Fossa. et al. | 2024-09-02 | Not public |
| Exhibit TW D 6 - FR Leaflet Cabazitaxel | 2024-09-02 | Not public |
| commentPreliminaryObjection | 2024-07-14 | Not public |
| Exhibit No. E.4 | 2024-07-14 | Not public |
| Exhibit No. E.3 | 2024-07-14 | Not public |
| Exhibit No. E.3 | 2024-07-14 | Not public |
| Exhibit No. E.6 | 2024-07-14 | Not public |
| Exhibit No. E.1.2 | 2024-07-14 | Not public |
| Written comments | 2024-07-14 | Not public |
| Exhibit No. E.8 | 2024-07-14 | Not public |
| Exhibit No. E.5 | 2024-07-14 | Not public |
| Exhibit No. E.1.1 | 2024-07-14 | Not public |
| Exhibit No. E.2 | 2024-07-14 | Not public |
| Exhibit No. E.1.3 | 2024-07-14 | Not public |
| Exhibit No. E.7 | 2024-07-14 | Not public |
| preliminaryObjection | 2024-07-02 | Not public |
| 240702_Sanofi-vs-Zentiva-Preliminary-Objection | 2024-07-02 | Not public |
| Exhibit_TW-D-1 | 2024-07-02 | Not public |
| Notification Of Service | 2024-06-13 | Not public |
| Proof of service | 2024-06-13 | Not public |
| Notification Of Service | 2024-06-11 | Not public |
| Proof of service | 2024-06-11 | Not public |
| Notification Of Service | 2024-06-06 | Not public |
| Proof of service | 2024-06-06 | Not public |
| Acknowledgement of access to case | 2024-06-04 | Not public |
| Acknowledgement of access to case | 2024-06-04 | Not public |
| Acknowledgement of access to case | 2024-06-03 | Not public |
| Panel-Appointment | 2024-06-03 | Not public |
| epoUploadDocumentsWorkflow | 2024-05-23 | Not public |
| Document from EPO | 2024-05-22 | Not public |
| Letter for Service | 2024-05-21 | Not public |
| Letter for Service | 2024-05-21 | Not public |
| Letter for Service | 2024-05-21 | Not public |
| Panel-Appointment | 2024-05-16 | Not public |
| EPO-Request-for-case-pending | 2024-05-16 | Not public |
| Receipt | 2024-05-16 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-05-16 | Not public |
| Exhibit No. D.1.2 | 2024-05-14 | Not public |
| Exhibit No. B.2.1 | 2024-05-14 | Not public |
| Exhibit No. 0.1 | 2024-05-14 | Not public |
| Exhibit No. C.1.2 | 2024-05-14 | Not public |
| Exhibit No. 0.2 | 2024-05-14 | Not public |
| Exhibit No. B.1.1.1 | 2024-05-14 | Not public |
| Exhibit No. D.2.2 | 2024-05-14 | Not public |
| Exhibit No. D.3 | 2024-05-14 | Not public |
| Exhibit No. 0.2 | 2024-05-14 | Not public |
| Exhibit No. C.1 | 2024-05-14 | Not public |
| Exhibit No. B.2.5 | 2024-05-14 | Not public |
| Exhibit No. 0.3 | 2024-05-14 | Not public |
| Exhibit No. 0.1 | 2024-05-14 | Not public |
| Exhibit No. B.1.1.2 | 2024-05-14 | Not public |
| Exhibit No. D.3.1 | 2024-05-14 | Not public |
| Exhibit No. B.1 | 2024-05-14 | Not public |
| Exhibit No. D.2.1 | 2024-05-14 | Not public |
| Exhibit No. B.2.4 | 2024-05-14 | Not public |
| Exhibit No. D.2.3 | 2024-05-14 | Not public |
| Exhibit No. A.1 | 2024-05-14 | Not public |
| Exhibit No. B.2.2 | 2024-05-14 | Not public |
| Exhibit No. A.1.1 | 2024-05-14 | Not public |
| Exhibit No. B.1.2 | 2024-05-14 | Not public |
| Exhibit No. D.1.1 | 2024-05-14 | Not public |
| Exhibit No. B.1.1 | 2024-05-14 | Not public |
| Exhibit No. 0.3 | 2024-05-14 | Not public |
| Statement of claim | 2024-05-14 | Not public |
| Statement of claim | 2024-05-14 | Not public |
| Exhibit No. B.2.3 | 2024-05-14 | Not public |
| Formal-checks_Request-for-correction | 2024-05-14 | Not public |
| Acknowledgement-of-lodging | 2024-05-13 | Not public |
| Exhibit No. C.1.2 | 2024-05-13 | Not public |
| Exhibit No. 0.2 | 2024-05-13 | Not public |
| Exhibit No. D.1.2 | 2024-05-13 | Not public |
| Exhibit No. C.1 | 2024-05-13 | Not public |
| Exhibit No. A.1 | 2024-05-13 | Not public |
| Exhibit No. B.1.1.2 | 2024-05-13 | Not public |
| Exhibit No. D.2.2 | 2024-05-13 | Not public |
| Exhibit No. 0.2 | 2024-05-13 | Not public |
| Exhibit No. D.2.1 | 2024-05-13 | Not public |
| Exhibit No. B.1.1.1 | 2024-05-13 | Not public |
| Exhibit No. B.1.1 | 2024-05-13 | Not public |
| Exhibit No. B.2.5 | 2024-05-13 | Not public |
| Exhibit No. D.3.1 | 2024-05-13 | Not public |
| Exhibit No. 0.3 | 2024-05-13 | Not public |
| Exhibit No. D.1.1 | 2024-05-13 | Not public |
| Exhibit No. B.2.3 | 2024-05-13 | Not public |
| Exhibit No. 0.3 | 2024-05-13 | Not public |
| Exhibit No. B.1.2 | 2024-05-13 | Not public |
| Exhibit No. D.3 | 2024-05-13 | Not public |
| Exhibit No. B.2.1 | 2024-05-13 | Not public |
| Exhibit No. D.2.3 | 2024-05-13 | Not public |
| Exhibit No. B.2.4 | 2024-05-13 | Not public |
| Exhibit No. 0.1 | 2024-05-13 | Not public |
| Exhibit No. A.1.1 | 2024-05-13 | Not public |
| Statement of claim | 2024-05-13 | Not public |
| Exhibit No. 0.1 | 2024-05-13 | Not public |
| Exhibit No. B.2.2 | 2024-05-13 | Not public |
| Exhibit No. B.1 | 2024-05-13 | Not public |